Figure 2.
Impact of MRD on the outcome of patients with AML in the context of ELN2017 risk classification. CIR and OS of patients who were MRD− categorized according to the ELN2017 classification compared with BAALC MRD+ (A-B) and MN1 MRD+ (C-D) patients or those with NPM1-mutated MRD (E-F).